Linda Yaccarino, who recently stepped down as the CEO of Elon Musk’s social media platform X, is making a surprising move into the health care industry. The digital health company eMed Population Health announced on Tuesday that it has appointed Yaccarino as its new CEO.
EMed is a startup focused on a booming new market: the blockbuster weight loss and diabetes drugs known as GLP-1s. The company is developing a platform to help manage the health of large populations using these incredibly popular medications. It’s a huge market, with some analysts predicting it could be worth $100 billion a year by 2030.
This is a big career shift for Yaccarino. Before her short tenure at X, she was a powerhouse in the advertising world, rising to the top of NBCUniversal’s global ad business. EMed said it hired her to help establish “game-changing partnerships” and navigate the complex health care market.
In a statement, Yaccarino said she sees a massive opportunity in health care. “The healthcare industry has been disrupted by technology, but not yet completely transformed by it,” she said.
Yaccarino left her role as CEO of X in July without giving a reason for her departure. Her move to eMed shows she’s ready for a new challenge in one of the fastest-growing and most competitive sectors of the economy.
